Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles.
about
TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells.Phorbol myristate acetate, but not CD40L, induces the differentiation of CLL B cells into Ab-secreting cells.A combination of cytokines rescues highly purified leukemic CLL B-cells from spontaneous apoptosis in vitro.TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets.The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells.Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia.Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.Modeling the chronic lymphocytic leukemia microenvironment in vitro.Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells.EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemia-like B-cell malignancies.Epigenetic regulation of WNT signaling in chronic lymphocytic leukemia.Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2.B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells.B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL.Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective.T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile.The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.Microenvironmental agonists generate phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCLThe functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemiaMimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go?Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia
P2860
Q33760295-748EF25D-680E-4486-8DF4-36AFC4867769Q34052050-5209A65A-586E-4BE2-B6BC-5ACB855646B1Q34653811-697DDD59-037C-4FE4-BA5A-84B50A79CDE9Q35861964-1C11AFDF-64CC-40C2-9AFB-630C66FF973AQ36021849-1F9741C9-BD77-4632-89E5-958AE0BF1921Q36133043-0F16511F-9C8D-41E5-BCDB-0159B144E815Q36326340-F0AE0F06-E15D-4E02-B200-2ED0ACBFF53FQ37378009-DDA1BB6F-B459-42B2-8606-67B6893CF717Q37910914-6C995D99-DA91-403B-8353-8BC2D52F73D8Q37971736-52417817-B208-4C03-B791-F736EB64EFEEQ38167332-872C67E0-E427-4E6E-8DD5-E74D375E6523Q38984569-CF695EF8-9C36-4AA1-B209-5EAADA5002B9Q39065374-BF66293B-8AEB-4270-9F17-5D4DE000DD60Q39328617-D855FA43-6634-49B5-A75B-D6F55D4AAD20Q40400031-2DD35852-77E0-4941-8386-EE5E1884D77EQ40525719-198D0C37-3A02-4B24-A8B9-2E4214E97995Q42217233-1A2975E8-2E4B-454E-813C-5A4E6D52195BQ42638970-91B13245-41DC-4E48-9953-E5B7E6E4399EQ42912844-A44321A5-8727-45AD-941A-E3B493D48DCDQ45833017-8D161A20-1888-4B69-A9B9-888CDE6FF713Q52579132-06E3F4BA-CE92-4CA2-BCB2-116C5E3DBD25Q54303388-D89CE38D-625A-4E0B-8C4A-06642F2DAB73Q54323506-1E6C9131-39BB-41A1-B259-557C6E33EC24Q55061968-C3196E94-4CD1-401B-AEA6-4212257B7C88Q56514276-F59D5B05-F27B-4D7B-97E2-D2952C94BAC3Q58042004-9C539D08-5321-4CBB-AA3D-EC69399579CAQ58319767-52A28173-3F70-4732-A5C2-47F1123167E9Q58436696-A6B9C985-E7C9-41A0-B194-263CC283B605
P2860
Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Different proliferative and su ...... tro model for pseudofollicles.
@ast
Different proliferative and su ...... tro model for pseudofollicles.
@en
type
label
Different proliferative and su ...... tro model for pseudofollicles.
@ast
Different proliferative and su ...... tro model for pseudofollicles.
@en
prefLabel
Different proliferative and su ...... tro model for pseudofollicles.
@ast
Different proliferative and su ...... tro model for pseudofollicles.
@en
P2093
P2860
P356
P1433
P1476
Different proliferative and su ...... tro model for pseudofollicles.
@en
P2093
F Hofstädter
G Brockhoff
S Diermeier-Daucher
P2860
P2888
P304
P356
10.1038/LEU.2009.145
P577
2009-08-06T00:00:00Z
P5875
P6179
1020317129